Table 2

HR for clinical and demographic parameters and increase of DAS to greater than 2.4 with restart of infliximab (univariable analysis)

HR (95% CI)Initial infliximabDelayed infliximab
Female gender1.1 (0.6 to 2.0)
Age1.00 (0.98 to 1.02)
RF positive1.2 (0.6 to 2.1)
ACPA positive1.5 (0.8 to 3.1)1.9 (0.8 to 4.5)1.08 (0.3 to 3.4)
SE positive3.9 (1.4 to 11.0)3.2 (0.97 to 10.9)7.0 (0.89 to 54.2)
Smoking2.4 (1.4 to 4.3)2.9 (1.5 to 5.8)1.2 (0.4 to 3.2)
BMI1.04 (0.96 to 1.12)
Infliximab delayed2.0 (1.1 to 3.7)
Symptom duration (months)1.02 (1.01 to 1.03)1.01 (0.99 to 1.03)1.02 (0.995 to 1.05)
Treatment duration (months)1.05 (1.02 to 1.07)1.07 (1.01 to 1.13)1.03 (0.999 to 1.07)
Infliximab dose increase1.2 (0.7 to 2.2)
DAS1.1 (0.7 to 1.9)
DAS <1.6 vs DAS ≤2.40.98 (0.5 to 1.8)
HAQ1.5 (0.8 to 3.0)
ESR1.00 (0.98 to 1.02)
CRP0.98 (0.93 to 1.02)
Tender joint count1.08 (0.93 to 1.27)
Swollen joint count0.97 (0.77 to 1.22)
Radiographic damage1.02 (1.00 to 1.03)
Erosion score1.03 (1.01 to 1.06)1.03 (0.99 to 1.07)1.03 (0.99 to 1.07)
Joint space narrowing1.03 (1.00 to 1.06)1.03 (0.99 to 1.07)1.02 (0.98 to 1.07)
Yearly change in SHS1.07 (1.02 to 1.13)1.08 (1.01 to 1.15)1.06 (0.98 to 1.15)
Disease activity (VAS)1.01 (0.99 to 1.02)
General health (VAS)1.00 (0.99 to 1.02)
Morning stiffness (VAS)1.01 (1.00 to 1.02)
Pain (VAS)1.01 (1.00 to 1.03)
Disease activity (doctor VAS)1.03 (1.01 to 1.06)1.03 (1.004 to 1.06)1.09 (1.01 to 1.18)
  • * Adjusted for age, gender and, with the exception of ‘infliximab delayed’, treatment timing.

  • ACPA, anti-citrullinated protein antibodies; BMI, body mass index; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; RF, rheumatoid factor; SE, shared epitope; SHS, Sharp/van der Heijde score; VAS, visual analogue scale (measured in mm).